News

Article

Pharmaceutical Technology

Pharmaceutical Technology, Trends in Formulation, October 2022
Volume2022 eBook
Issue 3
Pages: 4–9

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Author(s):

Feliza Mirasol

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Kalyakan/Stock.adobe.com – optimizing early drug candidate screening can save time and shorten drug discovery and development timelines.

Kalyakan/Stock.adobe.com

Time-to-market remains a significant factor in drug development today, as delays in timelines can often have costly and damaging effects, not only to the drug developer but to the patient. Challenges in the drug development cycle arise early in the drug candidate screening process. In this article, Industry players discuss how technological innovation and advances in analytical approaches enhance early drug candidate screening workflows to help shorten drug discovery and development timelines.

Read this article in Pharmaceutical Technology’s October 2022 Trends in Formulation eBook.

About the author

Feliza Mirasol is science editor for Pharmaceutical Technology.

Article Details

Pharmaceutical Technology
eBook: Trends in Formulation, October 2022
October 2022
Pages: 4–9

Citation

When referring to this article, please cite it as F. Mirasol, “Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk," Pharmaceutical Technology Trends in Formulation eBook (October 2022).

Articles in this issue
Small is a Powerful Ingredient for Patient-Centric Formulations
Small is a Powerful Ingredient for Patient-Centric Formulations
Kalyakan/Stock.adobe.com – optimizing early drug candidate screening can save time and shorten drug discovery and development timelines.
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
Sveta/Stock.adobe.com – Advances in technologies are being used to enhance the manufacturing of viral vectors for gene therapies at each step of the manufacturing process.
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Improved Formulations to Enable Stable Delivery of Biologics
Improved Formulations to Enable Stable Delivery of Biologics
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Emerging Applications of Vitamin E TPGS in Drug Delivery
Emerging Applications of Vitamin E TPGS in Drug Delivery

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
July 25th 2025

EMA Approves Lower GWP Alternative for Inhalation Medicine

Susan Haigney
The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Magnifier with pills on blue background | Image Credit: © Pixel-Shot - stock.adobe.com
July 23rd 2025

Overcoming PK/PD Modeling Challenges

Cynthia A. Challener
Artificial intelligence and machine learning can help identify complex patterns.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com
July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney
George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.